购物车
- 全部删除
- 您的购物车当前为空
GPX4-IN-13 (compound 16)作为一种抗癌活性的GPX4抑制剂,能够降低GPX4的表达,从而抑制甲状腺细胞的增殖并诱导铁死亡(ferroptosis)。此化合物在三个甲状腺癌细胞系—N-thy-ori-3-1(IC50=8.39 μM)、MDA-T32(IC50=10.28 μM)和MDA-T41(IC50=8.18 μM)—上展现出了显著的抑制效果。
GPX4-IN-13 (compound 16)作为一种抗癌活性的GPX4抑制剂,能够降低GPX4的表达,从而抑制甲状腺细胞的增殖并诱导铁死亡(ferroptosis)。此化合物在三个甲状腺癌细胞系—N-thy-ori-3-1(IC50=8.39 μM)、MDA-T32(IC50=10.28 μM)和MDA-T41(IC50=8.18 μM)—上展现出了显著的抑制效果。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mg | 询价 | 10-14周 | |
50 mg | 询价 | 10-14周 |
产品描述 | GPX4-IN-13 (compound 16), a GPX4 inhibitor, exhibits anticancer properties by diminishing the expression of GPX4, thereby reducing thyroid cell proliferation and inducing ferroptosis. Additionally, this compound effectively inhibits the growth of three distinct thyroid cancer cell lines: N-thy-ori-3-1 (IC 50 =8.39 μM), MDA-T32 (IC 50 =10.28 μM), and MDA-T41 (IC 50 =8.18 μM). |
分子量 | 353.37 |
分子式 | C23H15NO3 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.